CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 150 enrolled
Drug / intervention
Progesterone 200 MG +1 moredrug
Likely dose
Progesterone 200 MGfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05954962
NCT05954962Phase 4Completed
CompareCT.gov

Evaluation of the Efficacy of Micronized Natural Progesterone (Seidigestan®) vs GnRH Antagonist (Astarté®) in the Prevention of LH Peak During Controlled Ovarian Stimulation: a Randomized Clinical Trial.

Instituto Bernabeu·interventional·Posted Jul 20, 2023·Updated Mar 27, 2026

In Brief

A Phase 4 clinical trial evaluating Progesterone 200 MG and Ganirelix Acetate for IVF. Completed, enrolled 150 participants across 1 site.

Detailed Summary

This study aims to investigate if the use of oral micronized natural progesterone is not inferior to the use of subcutaneous antagonist in preventing LH peak in controlled ovarian stimulation.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIVF
CountriesSpain
Collaborators--

Timeline

Phase 4CompletedFinished
202420252026
First PostedJul 20, 2023
Enrollment StartDec 23, 2023
Primary CompletionApr 3, 2025
Study CompletionAug 30, 2025
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 2.9 years ago

Interventions

Progesterone 200 MGdrug

The patients in the study group will administer oral natural micronized progesterone capsules from day 1 of ovarian stimulation instead of "antagonist" (ganirelix) subcutaneaous injections from day 5-6 of stimulation.

Ganirelix Acetatedrug

The patients in the control group will administer subcutaneaous injections of ganirelix from day 5-6 of stimulation as per currently used protocol.